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Background. An increasing resistance of Helicobacter pylori strains to antimicrobial agents is the serious therapeutic problem.
The aim of this study was to compare the primary and secondary resistance of H. pylori strains isolated between 2006–2008 (data
published) and 2009–2011 to clarithromycin and levofloxacin.Material andMethods. 220 dyspeptic patients (153 before treatment,
67 after), were enrolled in the study. 51 H. pylori strains were isolated. MIC values of clarithromycin and levofloxacin were deter-
mined by the E-test method. The statistical analysis was conducted with the χ2 test with Yates correction at the 0.05 significance
level (P ≤ 0.05). Results. Between 2006 and 2008, 34% (39/115) of H. pylori strains were resistant to clarithromycin (primary 21%
(19/90), secondary 80% (20/25)). 5% (6/115) of strains were resistant to levofloxacin (primary 2% (2/90), secondary 16% ((4/25);
data published) Between 2009–2011, 22% (11/51) of H. pylori strains were resistant to clarithromycin (primary 19% (8/43),
secondary 38% (3/8)). 16% (8/51) of strains were resistant to levofloxacin (primary 12% (5/43), secondary 38% (3/8)).Conclusion.
The present study has shown the increasing amount of resistant H. pylori strains isolated from patients in Southern Poland to
levofloxacin and decreasing number of resistant strains to clarithromycin.
1. Introduction
Helicobacter pylori (H. pylori) is a Gram-negative, microae-
rophilic, and urease-positive spiral shaped bacterium, which
colonizes the gastric mucosa of 50% of the population
worldwide [1, 2]. The incidence of the infection is associated
mostly with childhood as well as socioeconomic and sanitary
conditions. Helicobacter pylori infection plays a major role in
peptic ulcer disease, low-grade mucosa-associated lymphoid
tissue (MALT) lymphoma, and gastric cancer. Thanks to the
discovery of this pathogen by Marshall and Warren in 1982,
peptic ulcer diseases are no longer chronic but can be cured
by the regimen of antibiotics and gastric antisecretory drugs
[3].
The preferred eradication therapy is triple or quadruple
therapy, which is combined therapy including three types
of drugs: antisecretory drugs, cytoprotectants, and antibi-
otics and chemotherapeutic drugs. Current guidelines from
the American College of Gastroenterology and the European
Helicobacter Study Group (EHSG) recommend a clarithro-
mycin-based triple therapy for the first 5 days (a proton
pump inhibitor (PPI) plus amoxicillin and clarithromycin)
or a bismuth quadruple therapy (a PPI plus bismuth, met-
ronidazole and tetracycline) [4, 5]. Obligatory procedures for
the management of H. pylori infection in Poland elaborated
upon by the Working Group of the Polish Society of Gas-
troenterology (PTG) are based on new guidelines from the
Third Maastricht Consensus Conference in 2005 [6].
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Current regimens of treatment H. pylori infection in
Poland are as follows.
(i) The First-Line Treatment. PPI, amoxicillin (1000mg),
and metronidazole (500mg) twice a day, 10–14 days,
and PPI, clarithromycin (500mg), and metronida-
zole (500mg) twice a day, 10–14 days, or PPI, amox-
icillin (500mg), and clarithromycin (500mg) twice a
day, 10–14 days.
(i) The Second-Line Treatment. PPI, amoxicillin
(1000mg), and metronidazole (500mg) twice a day
and tetracycline (250mg) three times daily prolonged
to 14 days, or PPI, amoxicillin (1000mg), and met-
ronidazole (500mg) twice a day and bismuth salts
(120mg) four times daily; prolonged to 14 days.
(i) The Third-Line Treatment. Evaluation of the sus-
ceptibility of the strains to the currently used anti-
microbial agents: amoxicillin, metronidazole, clar-
ithromycin, and tetracycline; possible introduction of
levofloxacin; adding a probiotic [6].
Recommendations of PTG were published in 2008 and
were the first polish recommendations which allow introduc-
tion of levofloxacin in treatment of H. pylori infection.
The increasing level of antibiotic resistance in H. pylori
strains had a drastic effect on the successful treatment [7, 8].
The most recent Maastricht guidelines recommend substi-
tuting metronidazole for clarithromycin in case where the
resistance level exceeds 15–20% [9]. However, according to
the Maastricht recommendation, if the resistance level to
metronidazole exceeds 40% and for clarithromycin 15–20%,
these antimicrobial agents should not be used or suscepti-
bility testing should be done. In addition, it recommends
local permanent monitoring of H. pylori susceptibility to
antimicrobial agents [5]. Emerging evidence indicates that
resistance rates to metronidazole could constitute the real
problem. On the other hand, some scientists believe that the
resistance might be overcome with increased doses of metro-
nidazole [10]. The rate of clarithromycin resistance is
increasing, and one of the reasons of this increase is likely
to be a greater use of clarithromycin in the treatment of res-
piratory tract infections in the community. Clarithromycin
resistance in H. pylori is associated with treatment failure,
although geographical variations were also observed [7, 11].
In Poland the resistance of H. pylori to antimicrobial drugs
used in the therapy is high and amounts to 28% to clar-
ithromycin (primary resistance 22%, secondary resistance
54%) and 46% to metronidazole (primary resistance 41%,
secondary resistance 68%) (data published by PTG) [6, 12].
Therefore, in accordance with the Maastricht recommenda-
tions, in Poland clarithromycin and metronidazole should
not be used without previous susceptibility testing [5].
When the first-line therapy is unsuccessful, we need the
effective second-line therapy. Evolving research has demon-
strated that the introduction of new drugs, such as levoflox-
acin and rifabutin, provides new possibilities of treatment
[7, 10, 11]. However, the current recommendation of PTG is
to entertain the introduction of levofloxacin as the third-line
empirical treatment [6]. Nevertheless, some studies carried
out by Molina-Infante in Spain examined the introduction
of levofloxacin in the first-line treatment in triple and
sequential regimens and demonstrated the advantage of
levofloxacin in both combinations. Levofloxacin may be a
good alternative to clarithromycin in the region with high
percentage of resistant H. pylori strains to clarithromycin.
[7, 11]. As a result of frequent resistance of H. pylori to clar-
ithromycin in Poland and recommendations of PTG (2008)
that enable the introduction of levofloxacin to H. pylori
eradication therapy, many physicians have started using the
levofloxacin in first-line treatment (data not published).
Levofloxacin, a bactericidal fluoroquinolone of the 3rd
generation antibiotics, has also the activity in the second-line
therapy. Levofloxacin may be used as a substitute for clar-
ithromycin in either a standard triple or sequential regimen.
A large study comparing antibiotics in either of regimens
shows a clear advantage to levofloxacin in both combina-
tions. It has been proposed that levofloxacin-based regimens
are the most beneficial in areas where clarithromycin resis-
tance is higher [13–16]. The introduction of levofloxacin to
the treatment scheme raises many hopes, but the resistance
to levofloxacin is a growing problem in Spain (from 6%
to more than 25% over the last 5 years) [17]. A rapidly
increasing rate of fluoroquinolone resistance was reported
in several countries [7]. The apparently rapid rate at which
fluoroquinolone resistance seems to develop may limit the
use of levofloxacin in H. pylori eradication to the second-line
therapy.
Since the resistance to antimicrobials is a major cause
of eradication failure, the monitoring of antimicrobial resis-
tance ofH. pylori in each domestic area should be warranted,
especially for clarithromycin and the commonly applied
metronidazole. Such monitoring is also recommended by
the Maastricht III Consensus. For developing countries this
monitoring should probably also include other antimicro-
bials used in the eradication therapy [18–20]. Therefore, the
aim of this prospective study was to assess the primary and
secondary resistance of H. pylori strains isolated from adult
patients, from the Malopolska region in Poland between
2006–2008 [13] and 2009–2011, to antibacterial drugs (clari-
thromycin and levofloxacin) used clinically for H. pylori
eradication.
2. Materials andMethods
2.1. Patients. The study enrolled a group of 220 dyspeptic
patients aged 16–87, who underwent gastroscopy in the
“Falck” Health Care Center in Krakow, Poland.
153 patients had never been treated for H. pylori infec-
tion, whereas 67 patients underwent theH. pylori eradication
therapy.
The plan of the study was approved by the Bioethical
Commission of the Jagiellonian University, and each patient
signed the informed consent for the participation in the
study.
2.2. Clinical Material. During gastroscopy two biopsy spec-
imens (bioptates) were taken from each patient. Bioptates
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were collected from the antrum and the body of the stomach.
Bioptates were transferred in a transportation medium,
Portagerm pylori (bioMe´rieux, Marcy-l’Etoile, France), and
then sent for microbiological tests, which were performed at
the Department of the Pharmaceutical Microbiology of the
Jagiellonian University Medical College.
2.3. Bacterial Culture and Susceptibility Testing. Bioptate was
homogenized in glass sterile mortars to ensure a homoge-
neous distribution of bacteria in the whole specimen. Homo-
genate was inoculated onto the solid medium, Schaedler agar
with 5% sheep blood added (bioMe´rieux, Marcy-l’Etoile,
France) and medium, Schaedler agar with 5% sheep blood,
and Dent selective supplement added (Helicobacter pylori
Selective Supplement-DENT, Oxoid, Basingstoke, UK). The
culture was carried out for 3 to 7 days under 5%CO2 at 37◦C.
The presence of H. pylori in the tested material was con-
firmed by the visual examination of the typical colonies
morphology on the plate with medium, positive biochemical
tests for catalase, oxidase, and urease. Furthermore, Gram-
staining preparation from the colony was performed to con-
firm the presence of Gram-negative spiral bacteria.
The susceptibility of H. pylori strains to antimicrobial
agents was assessed by the quantitative method, E-test
(AB Biodisk, Solna, Sweden), which determined the minimal
inhibitory concentration (MIC) of the drug that inhibits
the growth of bacterial strains. The susceptibility to clar-
ithromycin and levofloxacin was tested for each H. pylori
strain. From the pure H. pylori culture, one colony was taken
to prepare the suspension in 0.85% NaCl on an equivalent of
3.0 McFarland units. The inoculum was spread on the plate
with the Schaedler agar with 5% sheep blood (bioMe´rieux,
Marcy-l’Etoile, France) within 15 minutes after the prepara-
tion. Then, E-test stripes with the clarithromycin and levo-
floxacin gradient were placed on plates according to manual
of the manufacturer (AB Biodisk, E-test technical manual),
separately for clarithromycin and levofloxacin. Plates were
incubated in microaerophilic conditions at 37◦C for 72 hrs.
The breakpoints used to qualify strains as resistant
according to theMIC values were 1mg/L for both tested anti-
biotics, as previously described [21, 22].
The determination of MIC values was carried out against
the reference H. pylori strain from the American Type Cul-
ture Collection, ATCC 43504 Helicobacter pylori, to ensure
the quality of susceptibility tests.
2.4. Statistical Analysis. The statistical parameters such as:
mean values and chi-squared test of Independence (χ2 test)
were performed. The accepted significance level was 0.5
(results with P ≤ 0.05 were considered statistically signi-
ficant). In cases where the expected values were less than 5,
the Yates correction was used.
The association between the primary and the secondary
H. pylori resistance to the tested antibiotics was checked.
Moreover, the statistical analysis tested the differences
between the level of primary and secondary H. pylori resis-
tance to clarithromycin and levofloxacin in the years of our
study (2009–2011) and the previous study which was carried
The prevalence of H. pylori infection
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Figure 1: The prevalence of H. pylori infection among dyspeptic
patients enrolled in the study in 2009–2011.
out in the years 2006–2008, also in our Department and
showed the level of H. pylori resistance in the same region
of Southern Poland, Malopolska [13].
3. Results and Discussion
3.1. Results. Among 220 patients with dyspeptic symptoms
admitted to the study between January 2009 and December
2011, the presence ofH. pylori infections was confirmed in 51
cases. The prevalence ofH. pylori infections among dyspeptic
patients in Southern Poland amounted to 23% (51/220
Figure 1). The presence of H. pylori was confirmed by CLO
test—rapid urease test—performed by a doctor and bacterial
culture.
51 strains of H. pylori were successfully isolated from
biopsy specimens of 51 patients who were identified as
positive forH. pylori. The group ofH. pylori-positive patients
consisted of 28 women (55%) and 23 men (45%), which
indicates that both ganders were equally represented in the
study. The average age of this group of patients was 45.6 years
(aged 18–75 years).
In total, 43 strains were derived from patients who had
never been treated for H. pylori infections (primary strains
84%) and 8 strains were derived from patients after the failed
therapy (secondary strains 16%) (Figure 2).
Susceptibility to clarithromycin and levofloxacin was
tested for all H. pylori strains by the quantitative method, E-
test. The obtained MIC values ranged from 0.016 to 12mg/L
for clarithromycin and from 0.012 to 32mg/L for levofloxa-
cin. Mean MIC values were as follows: 1.22mg/L for clarith-
romycin and 1.42mg/L for levofloxacin.
In total, in the years 2009–2011, the ratio of H. pylori
strains susceptible to clarithromycin amounted to 78%
(40/51), while the ratio of resistant strains amounted to 22%
(11/51); primary resistance was 19% (8/43 strains) and sec-
ondary 38% (3/8 strains). The ratio of H. pylori strains
susceptible to levofloxacin amounted to 84% (43/51 strains),
while the ratio of resistant strains amounted to 16% (8/51
strains); primary resistance 12% (5/43), secondary 38% (3/8)
(Table 1).
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Figure 2: The percentage of primary and secondaryH. pylori strains
isolated from dyspeptic patients enrolled in the study in 2009–2011.
Table 1: Comparison of resistance of H. pylori primary and sec-
ondary strains to clarithromycin and levofloxacin in 2009–2011.
Antimicrobial
agent
No. (%) of resistant H. pylori strains in the
years 2009–2011
All strains Primary strains Secondary strains
n = 51 n = 43 n = 8
CLA(1) 11 (22%) 8 (19%) 3 (38%)
LEV(1) 8 (16%) 5 (12%) 3 (38%)
(1)
CLA: clarithromycin, LEV: levofloxacin.
In the years 2006–2008, 115 strains were isolated. 34%
(39/115) of H. pylori strains were resistant to clarithromycin
(primary 21% (19/90), secondary 80% (20/25)). 5% (6/115)
of strains were resistant to levofloxacin (primary 2% (2/90),
secondary 16% (4/25)) [13].
The comparison of the H. pylori-resistant strains to
clarithromycin and levofloxacin, isolated between 2006–2008
[13] and 2009–2011, was conducted with the use of the
χ2 test. An increase of the amount of resistant strains to
levofloxacin was statistically significant; 5% (6/115) between
2006 and 2008 [13] versus 16% (8/51) between 2009 and
2011, P = 0.05 (with the Yates correction).
Nevertheless, the amount of H. pylori-resistant strains to
clarithromycin is decreasing. The total amount of resistant
strains decrease from 34% in 2006–2008 [13] to 22% in
2009–2011; however it is statistically insignificant (P = 0.16
(Table 2, Figure 3)).
4. Discussion
Variations of the prevalence of resistant H. pylori strains
depend on some factors, for instance, the use of antibiotics
and chemotherapeutics in recommended patterns of antimi-
crobial agents, and are geographically differentiated [23].
Table 2: Comparison of resistance of H. pylori strains to clarithro-
mycin and levofloxacin between 2006–2008 [13] and 2009–2011.
Antimicrobial
agent
No. (%) of H. pylori-resistant strains
2006–2008 [13] 2009–2011
P value(1)
n = 115 n = 51
CLA(2) 39 (34%) 11 (22%) 0,16 NS(3)
LEV(2) 6 (5%) 8 (16%) 0,05(4)
(1)
P value (chi-square test) with the Yates correction. P≤ 0.05 was deemed
statistically significant.
(2)CLA: clarithromycin, LEV: levofloxacin.
(3)NS: non significant.
(4)Statistically significant differences between the level of resistance in the
years 2006–2008 and 2009–2011.
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Figure 3: Activity of clarithromycin and levofloxacin against pri-
mary and secondary H. pylori strains. ∗statistically significant dif-
ferences between the level of resistance to levofloxacin in the years
2006–2008 and 2009–2011.
The resistance of H. pylori strains to levofloxacin is
quickly acquired; thus, it is the growing problem [7, 23]. For
example, in France it increased from 3.3% in 1999 to 17.5%
in 2003 [21]; in Spain the resistance increased from 6% to
more than 25% over the last five years [17, 24]. In another
country, such as Iran, the resistance of H. pylori to fluoro-
quinolones has also been increasing although it had not been
reported before—primary resistance has amounted to 5.3%
for levofloxacin [18].
Our study has shown that in Poland there is also a sig-
nificant increase of H. pylori strains resistant to levofloxacin,
from 5% in 2006–2008 [13] to 16% in 2009–2011 (P = 0.05).
Many studies have shown that resistance to fluoroquinolones
is easily acquired and is due to point mutations in gyrA genes
[21, 23, 25, 26]. The higher rate of H. pylori-resistant strains
may be caused by the more frequent use of levofloxacin
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in the treatment of H. pylori infections. Studies conducted
in Belgium over the last 20 years (1990–2009) show the
correlation between consumption of antibiotics and the rates
of resistant H. pylori strains [27]. Also another study, carried
out by Cabrita et al. in Portugal, shows the correlation
between increased use of antibiotics and the growth in
prevalence of resistant H. pylori strains to these antibiotics
[28]. Nevertheless, there is no commonly available informa-
tion about usage of antibiotics and chemotherapeutics in
outpatient clinic in Poland, but, as known, fluoroqinolones
are used not only in H. pylori infection but also in treatment
of infections of genitourinary tract and respiratory tract,
gastrointestinal diseases, infection of skin and soft tissues,
and many others [25, 29, 30]. This usage of fluoroquinolones
and cited studies allows to conclude that increasing resistance
of H. pylori strains to levofloxacin in Southern Poland may
be caused by more common use of levofloxacin and other
fluoroquinolones in community and also in treatment of H.
pylori infections. Susceptibility testing has not been routinely
performed and anti-H. pylori drugs like levofloxacin are used
in the empirical therapy as suggested by many researchers.
However, due to the fact that the resistance to levofloxacin
is quickly acquired, susceptibility testing should be routinely
carried out to enable properly selecting treatment model,
or levofloxacin should not be used commonly but only in
the rescue third-line therapy, when treatment with clarithro-
mycin and metronidazole failed (as it is recommended by
EHSG and PTG [5, 6]) to avoid the further increase of
resistance ofH. pylori to antimicrobial agents [31].Moreover,
Marzio et al. dealt with the role of preliminary susceptibility
testing before therapy and after failed therapy. It has been
suggested that triple therapy with levofloxacin, amoxicillin,
and PPI should not be used without previous susceptibility
test in the region where primary resistance of H. pylori to
levofloxacin amounted to 10% [32]. In our study, 16% of
H. pylori strains was resistant to levofloxacin and primary
resistance 12%.
According to EHSG and the Polish Society of Gastro-
enterology recommendations, there are three schemes of
treatment which suggested the use of levofloxacin as the
third-line treatment [5, 6]. Moreover, several studies which
showed the efficacy of the third-line rescue therapy with levo-
floxacin were carried out [31, 33, 34]. Furthermore, levoflox-
acin was also successfully tested as a good substitute of
clarithromycin in the area with the high prevalence of
clarithromycin-resistant H. pylori strains [7, 35] and as a
good alternative for patients allergic to penicillin [36].
Positive results of these studies were likely to con-
tribute to the increased use of levofloxacin instead of clari-
thromycin in the empirical treatment. Apart from that, flu-
oroquinolones as drugs with a broad spectrum of activity
against bacteria are commonly used in the treatment of many
diseases, not only in the treatment of H. pylori infections.
An interesting result shown by our research is the change
in the profile of the susceptibility of H. pylori strains isolated
from patients in Southern Poland to clarithromycin. The
resistance to clarithromycin decreased in comparison to the
previous years 2006–2008. The current level of resistance of
H. pylori to clarithromycin has amounted to 22%, while in
2006–2008 it was equal to 34% [13]. This change may be
caused by the lower consumption of this antimicrobial agent
and higher consumption of levofloxacin instead of clar-
ithromycin. This proposal is due to the changes in the profile
of H. pylori susceptibility and the previously cited studies
indicating the relationship between the amount of drug con-
sumption and the amount of resistance of H. pylori strains to
this drug [27]. It is a hypothesis which would require further
detailed research and analysis. However, as the Maastricht III
Consensus Report recommended, we carry out the monitor-
ing of antibiotics resistance of H. pylori strains in our region
of Poland—Southern Poland.
Interesting results have been obtained in Brazil, the
research shows that the resistance to clarithromycin is lower
than that to levofloxacin (8% versus 23%), which suggests
that clarithromycin is still a good option in the treatment of
H. pylori infections [16]. If the level of resistance to levoflox-
acin continues to rise and the downward trend of resistance
to clarithromycin is sustained, a similar situation may occur
in Poland.
5. Conclusion
All things considered, it should be noted that the resistance
of H. pylori strains is changing and depends on commonly
used antimicrobial agents, so the obligatory susceptibility
testing before the treatment would be a much better solution
to avoid the further increase of resistance of H. pylori and
other bacteria to antibiotics commonly used in treatment of
H. pylori infection [31]. Moreover, the present study shows
rapidly increasing resistance ofH. pylori strains isolated from
patients in Poland, to levofloxacin. That could discourage the
use of this fluoroquinolone in the empirical first-line therapy
of H. pylori infections and suggest that it should be avoided
to overuse of levofloxacin as a first-line therapy. Thus, H.
pylori resistance to clarithromycin should be permanently
monitored due to the variability of the prevalence of resistant
H. pylori strains.
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